COVID-19
Conditions
Interventions
Paxlovid Group:Orally take Nirmatrelvir tables(300mg) and Ritonavir tables(100mg), 12h/time, for 5 consecutive days
Control Group:standard treatments
Sponsors
Shijiazhuang People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria are as follows: (1) Newly diagnosed COVID-19 patients with positive nucleic acid test in Shijiazhuang city who have not received systemic treatment; (2) patients with mild or moderate COVID-19 type within 5 days of onset, classified according to the “Diagnosis and Treatment Guide for COVID-19 (Version 9)”; (3) voluntary participation and informed consent for the clinical trial.
Exclusion criteria
Exclusion criteria: Exclusion criteria are as follows: (1) Patients with any psychiatric illness who cannot cooperate with the study; (2) Patients who meet the contraindications for the medication under investigation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time of first nucleic acid negative;Two consecutive nucleic acid negative times;Nucleic acid negative rate after 3 days of treatment;Nucleic acid negative rate after 5 days of treatment;Nucleic acid negative rate after 7 days of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Main symptom relief time;hospital stay;incidence of sequelae; | — |
Countries
China
Contacts
Public ContactYubin Zhao
Shijiazhuang People's Hospital
Outcome results
None listed